<DOC>
	<DOCNO>NCT00845546</DOCNO>
	<brief_summary>The objective study compare single-dose relative bioavailability Ranbaxy Schering ( Claritin-D® 24 hour ) 10 mg Loratadine/240 mg Pseudoephedrine Sulfate Extended-Release Tablets , fully replicate design , fed condition .</brief_summary>
	<brief_title>Bioequivalence Study Loratadine / Pseudoephedrine Sulfate 10/ 240 mg Extended-Release Tablets Under Fed Conditions</brief_title>
	<detailed_description>The study conduct open-label , randomize , Single-Dose , Fully replicate , 4-way Crossover Study compare single-dose relative bioavailability Ranbaxy Schering ( Claritin_D® 24 hour ) 10 mg Loratadine/240 mg Pseudoephedrine Sulfate Extended-Release Tablets , Healthy adult Volunteers Under Fed Conditions In period , subject house evening dose 36 hour blood draw return subsequent blood draw 48 , 72 , 96 120 hour post dose . Single oral 10 mg Loratadine/ 240 mg Pseudoephedrine Sulfate dos separate washout period 21 day . A total 40 subject 1 alternate ( 34 male 7 female ) include study , 37 ( 32 male 5 female ) finish study accord protocol .</detailed_description>
	<mesh_term>Pseudoephedrine</mesh_term>
	<mesh_term>Ephedrine</mesh_term>
	<mesh_term>Loratadine</mesh_term>
	<criteria>Healthy adult male female volunteer , 1845 year agestart study . Other birth control method may deem acceptable Postmenopausal woman amenorrhea least 2 year eligible Voluntarily consent participate study History presence significant cardiovascular , pulmonary , hepatic , renal , hematologic , gastrointestinal , endocrine , immunologic , dermatologic , neurologic , psychiatric disease In addition , history presence : alcoholism drug abuse within past year hypersensitivity idiosyncratic reaction Loratadine H1receptor antagonist hypersensitivity idiosyncratic reaction Pseudoephedrine sympathomimetic amine Glaucoma hypermetropia Subjects receive monoamine oxidase ( MAO ) inhibitor within 14 day stop use MAO inhibitor , sympathomimetic amine Subjects use drug substance know strong inhibitor CYP ( cytochrome P450 ) enzymes within 10 day study start Subjects use drug substance know strong inducer CYP ( cytochrome P450 ) enzymes within 28 day study start Female subject pregnant lactating Subjects abnormal diet ( whatever reason ) 28 day prior first dose Subjects , completion study , would donate excess : 500 mL blood 14 day 500750 mL blood 14 day ( unless approve principal Investigator ) 1000 mL blood 90 day 1250 mL blood 120 day 1500 mL blood 180 day 2000 mL blood 270 day 2500 mL blood 1 day Subjects participate another clinical trial within 28 day prior study start</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Bioequivalence 10 mg Loratadine 240 mg Pseudoephedrine Sulfate Extended Release Tablets</keyword>
</DOC>